Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

NCT03878095 PHASE2 ACTIVE_NOT_RECRUITING Results posted

This phase II trial studies how well olaparib and ceralasertib (AZD6738) work in treating patients with IDH mutant cholangiocarcinoma or solid tumors. Cancer is caused by changes (mutations) to genes that control the way cells function. Laboratory studies have shown that olaparib and AZD6738 can shrink IDH mutant tumors or stop them from growing. Olaparib and ceralasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Details

Lead sponsor	National Cancer Institute (NCI)
Phase	PHASE2
Status	ACTIVE_NOT_RECRUITING
Enrolment	24
Start date	Thu Jan 30 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jul 10 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Malignant Solid Neoplasm
• Refractory Cholangiocarcinoma
• Refractory Malignant Solid Neoplasm

Interventions

• Biopsy Procedure
• Biospecimen Collection
• Bone Marrow Aspiration
• Bone Marrow Biopsy
• Ceralasertib
• Computed Tomography
• Magnetic Resonance Imaging
• Olaparib

Countries

United States